AstraZeneca unveiled plans to invest in end‑to‑end cell‑therapy capabilities in Shanghai, including a manufacturing and supply base plus an innovation center for early research, clinical manufacturing and regulatory support. The move follows AstraZeneca’s multi‑billion‑dollar commitment to China and reflects the company’s pivot to scale cell‑therapy production for Asian markets. Company statements and industry reporting said the Shanghai plant will support CAR‑T and next‑generation cell therapies acquired through deals and internal programs. The investment signals multinational pharma strategy to localize advanced biologics manufacturing and compress timelines for Asia‑focused trials and regulatory filings.